$1.05
-0.05 (-4.55%)
Open$1.10
Previous Close$1.10
Day High$1.10
Day Low$1.01
52W High$2.60
52W Low$1.09
Volume—
Avg Volume235.5K
Market Cap31.30M
P/E Ratio—
EPS$-0.69
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,506.7% upside
Current
$1.05
$1.05
Target
$16.87
$16.87
$11.09
$16.87 avg
$25.84
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 47.1K | 91.7K | 11.20M |
| Net Income | -43,663,336 | -76,572,491 | 1.78M |
| Profit Margin | -91,866.0% | -87,272.7% | 15.9% |
| EBITDA | -44,962,433 | -83,231,315 | 2.32M |
| Free Cash Flow | — | — | 977.1K |
| Rev Growth | -48.7% | -48.7% | +3.1% |
| Debt/Equity | — | — | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |